Errors in the Methods, Results, and Table 2 - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Corrections to the Methods, Results, and Table 2

  • November 1, 2026

Share

Clinical Scorecard: Corrections to the Methods, Results, and Table 2

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Corrections to the Methods, Results, and Table 2
Key MechanismsThe correction specifies how annual and mean PFB diagnosis prevalence was calculated and clarifies the sensitivity-analysis wording and Table 2 labels; reported values and study conclusions are unchanged.
Target PopulationPatients or participants described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • Annual PFB diagnosis prevalence was calculated per 10,000 veterans receiving VHA outpatient care, with 95% CIs.
  • Mean prevalence for fiscal years 2016-2022 was calculated overall and by age, and within sex strata according to self-reported race and ethnicity.
  • A sensitivity analysis requiring at least 2 PFB encounters separated by 30 days or more found prevalence of 5.6 (95% CI, 5.5-5.7) per 10,000 veterans.
  • Prevalence estimates use a denominator-based expression per 10,000 veterans; prevalence ratios are unitless.
  • The article was corrected; reported values and study conclusions were not altered.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Veterans receiving VHA outpatient care in fiscal years 2016-2022; the correction provides no prescribing data.

          The correction addresses prevalence reporting and does not provide treatment recommendations.

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Related Content